Reuse of drugs in the treatment of COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/28484 |
Resumo: | After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects. |
id |
UNIFEI_c9ff838381076a5126a51d5a6d8bd3f8 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/28484 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Reuse of drugs in the treatment of COVID-19Reutilización de medicamentos en el tratamiento del COVID-19Reutilização de fármacos no tratamento da COVID-19CloroquinaHidroxicloroquinaIvermectinaAzitromicinaSARS-CoV-2.CloroquinaHidroxicloroquinaIvermectinaAzitromicinaSARS-CoV-2.ChloroquineHydroxychloroquineIvermectinAzithromycinSARS-CoV-2.After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects.Tras un brote de neumonía atípica en la ciudad de Wuhan, China, hubo alertas epidemiológicas por el factor desconocido. El 7 de enero de 2020, científicos chinos aislaron una cepa de coronavirus, en la que se identificó el agente etiológico. Rápidamente se propagó por todo el mundo y, por ello, fue declarada pandemia el 11 de marzo de 2020. A partir de entonces, surge la necesidad de buscar tratamientos y prevención de la enfermedad, a través de algunos fármacos existentes, como la Cloroquina, Hidroxicloroquina, Ivermectina. y azitromicina. Objetivo: El objetivo de este estudio es discutir los medicamentos existentes utilizados para el posible tratamiento de la COVID-19, esclarecer sus mecanismos de acción y estudios que comprueben su eficacia o no. Metodología: La revisión narrativa de la literatura se basó en una búsqueda en las bases de datos de las revistas Google Scholar, Capes, Scielo y PubMed publicadas en los últimos 3 años, utilizando los términos: “covid-19 drogas in vitro/in vivo”; "SARS-CoV-2"; "coronavirus". Resultados: Del análisis de los artículos, se puede notar que no existe suficiente evidencia que demuestre la efectividad de estos medicamentos en la lucha contra el COVID-19. Los estudios que mostraron resultados en el combate al SARS-CoV-2 fueron in vitro, además de ser a dosis superiores a las recomendadas para humanos. Conclusión: Por lo tanto, aún no se ha esclarecido y determinado su seguridad terapéutica para la prevención y tratamiento de la COVID-19, por lo que su uso indiscriminado puede potenciar efectos adversos.Após surto de pneumonia atípica na cidade de Wuhan, na China, ocorreram alertas epidemiológicos devido ao fator desconhecido. Em 7 de janeiro de 2020, cientistas chineses isolaram uma cepa de coronavírus, na qual foi identificado o agente etiológico. Logo se espalhou rapidamente pelo mundo e, por isso, foi declarada pandemia em 11 de março de 2020. A partir de então, surge a necessidade de buscar por tratamentos e prevenção da doença, por meio de alguns fármacos já existentes, como a Cloroquina, Hidroxicloroquina, Ivermectina e Azitromicina. Objetivo: O objetivo deste estudo é discutir sobre os medicamentos já existentes utilizados para o possível tratamento da COVID-19, esclarecer seus mecanismos de ação e estudos que comprovam sua eficácia ou não. Metodologia: A revisão narrativa da literatura foi baseada na busca nas bases de dados Google Acadêmico, Periódicos Capes, Scielo e PubMed publicados nos últimos 3 anos, por meio dos termos: “medicamentos covid-19 in vitro/in vivo”; “sars-cov-2”; “coronavírus”. Resultados: A partir da análise dos artigos, pode-se notar que não existem evidências suficientes para comprovar eficácia desses medicamentos no combate a COVID-19. Os estudos que mostraram resultados no combate ao SARS-CoV-2 foram in vitro, além de estarem em doses mais elevadas do que o recomendado para humanos. Conclusão: Portanto, a sua segurança terapêutica para a prevenção e tratamento da COVID-19 ainda não foi esclarecida e determinada, assim, o seu uso indiscriminado pode potencializar os efeitos adversos.Research, Society and Development2022-04-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2848410.33448/rsd-v11i5.28484Research, Society and Development; Vol. 11 No. 5; e43311528484Research, Society and Development; Vol. 11 Núm. 5; e43311528484Research, Society and Development; v. 11 n. 5; e433115284842525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/28484/24720Copyright (c) 2022 Alessandra Isabô Neri; Lílian Carla Carneiro; Cristiene Costa Carneiro; Aroldo Vieira de Moraes Filho; Lee Chen-Chenhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessNeri, Alessandra Isabô Carneiro, Lílian CarlaCarneiro, Cristiene CostaMoraes Filho, Aroldo Vieira deChen-Chen, Lee2022-04-17T18:18:56Zoai:ojs.pkp.sfu.ca:article/28484Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:52.257472Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Reuse of drugs in the treatment of COVID-19 Reutilización de medicamentos en el tratamiento del COVID-19 Reutilização de fármacos no tratamento da COVID-19 |
title |
Reuse of drugs in the treatment of COVID-19 |
spellingShingle |
Reuse of drugs in the treatment of COVID-19 Neri, Alessandra Isabô Cloroquina Hidroxicloroquina Ivermectina Azitromicina SARS-CoV-2. Cloroquina Hidroxicloroquina Ivermectina Azitromicina SARS-CoV-2. Chloroquine Hydroxychloroquine Ivermectin Azithromycin SARS-CoV-2. |
title_short |
Reuse of drugs in the treatment of COVID-19 |
title_full |
Reuse of drugs in the treatment of COVID-19 |
title_fullStr |
Reuse of drugs in the treatment of COVID-19 |
title_full_unstemmed |
Reuse of drugs in the treatment of COVID-19 |
title_sort |
Reuse of drugs in the treatment of COVID-19 |
author |
Neri, Alessandra Isabô |
author_facet |
Neri, Alessandra Isabô Carneiro, Lílian Carla Carneiro, Cristiene Costa Moraes Filho, Aroldo Vieira de Chen-Chen, Lee |
author_role |
author |
author2 |
Carneiro, Lílian Carla Carneiro, Cristiene Costa Moraes Filho, Aroldo Vieira de Chen-Chen, Lee |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Neri, Alessandra Isabô Carneiro, Lílian Carla Carneiro, Cristiene Costa Moraes Filho, Aroldo Vieira de Chen-Chen, Lee |
dc.subject.por.fl_str_mv |
Cloroquina Hidroxicloroquina Ivermectina Azitromicina SARS-CoV-2. Cloroquina Hidroxicloroquina Ivermectina Azitromicina SARS-CoV-2. Chloroquine Hydroxychloroquine Ivermectin Azithromycin SARS-CoV-2. |
topic |
Cloroquina Hidroxicloroquina Ivermectina Azitromicina SARS-CoV-2. Cloroquina Hidroxicloroquina Ivermectina Azitromicina SARS-CoV-2. Chloroquine Hydroxychloroquine Ivermectin Azithromycin SARS-CoV-2. |
description |
After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04-12 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/28484 10.33448/rsd-v11i5.28484 |
url |
https://rsdjournal.org/index.php/rsd/article/view/28484 |
identifier_str_mv |
10.33448/rsd-v11i5.28484 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/28484/24720 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 5; e43311528484 Research, Society and Development; Vol. 11 Núm. 5; e43311528484 Research, Society and Development; v. 11 n. 5; e43311528484 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052709884395520 |